This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Amryt Pharma Past Earnings Performance
Past criteria checks 0/6
Key information
34.4%
Earnings growth rate
59.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 32.7% |
| Return on equity | -0.2% |
| Net Margin | -0.3% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Amryt Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 244 | -1 | 124 | 38 |
| 30 Jun 22 | 239 | 3 | 119 | 41 |
| 31 Mar 22 | 233 | 3 | 112 | 39 |
| 31 Dec 21 | 223 | 1 | 100 | 38 |
| 30 Sep 21 | 210 | -88 | 90 | 34 |
| 30 Jun 21 | 203 | -81 | 83 | 30 |
| 31 Mar 21 | 186 | -92 | 82 | 28 |
| 31 Dec 20 | 183 | -105 | 81 | 28 |
| 30 Sep 20 | 180 | -87 | 80 | 31 |
| 30 Jun 20 | 140 | -92 | 68 | 26 |
| 31 Mar 20 | 98 | -87 | 52 | 23 |
| 31 Dec 19 | 58 | -63 | 36 | 16 |
| 31 Dec 18 | 17 | -30 | 18 | 11 |
Quality Earnings: 3N9A is currently unprofitable.
Growing Profit Margin: 3N9A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3N9A is unprofitable, but has reduced losses over the past 5 years at a rate of 34.4% per year.
Accelerating Growth: Unable to compare 3N9A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3N9A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.1%).
Return on Equity
High ROE: 3N9A has a negative Return on Equity (-0.24%), as it is currently unprofitable.